BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm's coronavirus vaccine candidate that has completed early-stage trials in China, an executive said.Fosun will focus instead on seeking Chinese approval for BioNTech's other experimental vaccine which is in final-stage human trials in the United States, Fosun's Chief Medical Officer Hui Aimin told Reuters in an interview.The vaccine candidate developed by BioNTech and US drugmaker Pfizer Inc is under real-time regulatory review in Europe and could seek emergency use authorisation in the United States after enough safety data is provided as early as this month.But the candidate known as BNT162b2 missed an earlier.